Stocks Health care AMGN
NASDAQ · Health careAmgen Inc (AMGN)
Amgen Inc brought in $38.1B of revenue over the twelve months to June 30, 2026, up 9.1% from a year earlier. Net income was $8.7B, a net margin of 23.0%. Operating cash flow minus capital spending left $8.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $14B in cash against $57.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
Key facts about Amgen Inc
- Net worth
- Amgen Inc has a market value (market cap) of $224.7B at the latest share price, and shareholders' equity of $11.7B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $36.8B (+10.0% year on year), with net income of $7.7B. Over the 12 months to June 30, 2026: revenue $38.1B, net income $8.7B.
- Cash flow
- In fiscal 2025 operations brought in $10B of cash; after $1.9B of capital spending, free cash flow was $8.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 5, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Amgen Inc's next report is expected around November 3, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Amgen Inc declared dividends of $9.66 per share in fiscal 2025, a yield of 2.32% at the current price.
What Amgen Inc does
Amgen discovers, develops, and manufactures biologic medicines based on recombinant DNA technology. It produces prescription drugs treating cancer, kidney disease, rheumatoid arthritis, and bone conditions, which it sells to hospitals, clinics, and pharmacies. Its shares trade on NASDAQ under the ticker AMGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $36.8B | $7.7B | $14.23 | $8.1B |
| 2024 | $33.4B | $4.1B | $7.56 | $10.4B |
| 2023 | $28.2B | $6.7B | $12.49 | $7.4B |
| 2022 | $26.3B | $6.6B | $12.11 | $8.8B |
| 2021 | $26B | $5.9B | $10.28 | $8.4B |
| 2020 | $25.4B | $7.3B | $12.31 | $9.9B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AMGN ranks in Health care
Dividends
Amgen Inc declared $9.66 per share in fiscal 2025. At the current price that is a yield of 2.32%. It paid out $5.1B in cash dividends, 66% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $9.66 | $5.1B | 66% |
| 2024 | $9.13 | $4.8B | 118% |
| 2023 | $8.64 | $4.6B | 68% |
| 2022 | $7.95 | $4.2B | 64% |
| 2021 | $7.22 | $4B | 68% |
| 2020 | $6.56 | $3.8B | 52% |
Latest SEC filings
What Amgen Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.5% to $10.1B versus the same quarter last year; diluted EPS $4.37 versus $2.65.
- August 4, 2026
- July 31, 2026
- June 11, 2026
- June 11, 2026
- May 20, 2026
- May 19, 2026
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 5.8% to $8.6B versus the same quarter last year; diluted EPS $3.34 versus $3.20.
- April 30, 2026
What is AMGN worth? A DCF from its reported cash flow
Insider trades
What the people running Amgen Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $4.1M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 13, 2026 | Khosla RachnaSVP, Business Development | Exercised options | 1,252 | $203.6K |
| August 13, 2026 | Khosla RachnaSVP, Business Development | Sold | 1,252 | $521.4K |
| August 11, 2026 | Khosla RachnaSVP, Business Development | Sold | 2,000 | $825.1K |
| August 7, 2026 | Busch Matthew C.VP, Finance & CAO | Received as pay | 730 | - |
| August 7, 2026 | Drake Michael VDirector | Received as pay | 64 | - |
| August 7, 2026 | Holley Charles MDirector | Received as pay | 103 | - |
| August 7, 2026 | Ishrak OmarDirector | Received as pay | 85 | - |
| August 6, 2026 | Grygiel Nancy A.SVP & CCO | Exercised options | 1,970 | $349.6K |
Who owns AMGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.51% | April 29, 2026 |
| Capital World Investors13G, passive | 5.5% | May 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 3,146 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 49,362,016 | +2,261,544 |
| Vanguard Capital Management LLC | 35,250,101 | +235,869 |
| State Street Corp | 30,560,537 | +12,049 |
| Capital World Investors | 29,075,329 | -213,014 |
| Invesco Ltd. | 16,320,446 | +434,940 |
| Geode Capital Management, LLC | 15,696,068 | +265,544 |
| Charles Schwab Investment Management Inc | 15,034,038 | +2,260,652 |
| Vanguard Portfolio Management LLC | 14,853,366 | +232,218 |
| Morgan Stanley | 13,653,692 | -2,182,366 |
| Wells Fargo & Company | 7,235,462 | +147,452 |
| Primecap Management Co | 6,756,962 | -2,117,167 |
| Capital Research Global Investors | 6,272,625 | -682,720 |
| Northern Trust Corp | 6,200,994 | -16,844 |
| Norges Bank | 5,625,584 | new |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 5,390,910 | +605,928 |
| Bank of America Corp | 5,058,830 | -62,198 |
| Royal Bank of Canada | 4,328,785 | -142,660 |
| Goldman Sachs Group Inc | 4,130,732 | -89,257 |
| Amundi | 3,890,189 | +512,883 |
| Legal & General Group Plc | 3,816,942 | -53,921 |
Insiders
22 insiders reported holding 956,181 shares in total, about $397.4M at the last price.
| Holder | Shares |
|---|---|
| Bradway Robert AChairman, CEO and President, Director | 505,160 |
| Santos EstebanEVP, Operations | 82,847 |
| Gordon MurdoEVP, Global Commercial Ops | 51,222 |
| Griffith Peter H.EVP & CFO | 50,150 |
| Reese David MEVP & Chief Technology Officer | 42,256 |
| Graham Jonathan PEVP & Gen. Counsel & Sec. | 39,712 |
| Bradner James E.EVP, Research and Development | 30,016 |
| Eckert RobertDirector | 26,251 |
| Jacks TylerDirector | 18,284 |
| Kullman Ellen JamisonDirector | 14,536 |
Questions about AMGN
What does Amgen Inc do?
Amgen discovers, develops, and manufactures biologic medicines based on recombinant DNA technology. It produces prescription drugs treating cancer, kidney disease, rheumatoid arthritis, and bone conditions, which it sells to hospitals, clinics, and pharmacies. Its shares trade on NASDAQ under the ticker AMGN.
What is Amgen Inc's net worth?
Amgen Inc has a market value (market cap) of $224.7B at the latest share price, and shareholders' equity of $11.7B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Amgen Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $8.7B on revenue of $38.1B, a net margin of 23.0%.
How much revenue does Amgen Inc make?
Over the twelve months to June 30, 2026 Amgen Inc reported revenue of $38.1B. That is 9.1% more than a year earlier.
When did Amgen Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 4, 2026.
When is Amgen Inc's next earnings report?
Amgen Inc's next report is expected around November 3, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Amgen Inc pay a dividend?
Yes. Amgen Inc declared dividends of $9.66 per share in fiscal 2025, a yield of 2.32% at the current price.
Similar companies
Compare AMGN with
Follow AMGN
Get an email when Amgen Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Amgen Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.